An NIH study of 50,884 women found two forever chemicals most people still carry were linked to nearly double the rate of one aggressive type of breast cancer
Most people still carry measurable amounts of PFAS, the so-called forever chemicals, in their blood, even though the best-known ones were largely phased out years ago. NIH researchers measured 17 of these chemicals in blood samples from women in the Sister Study, drawn years before any of them had cancer. They compared 1,609 women who later developed breast cancer with 2,269 women in a comparison group.
For breast cancer overall, the two best-known forever chemicals showed no clear link. The signal appeared in one subtype: estrogen receptor-negative breast cancer, a more aggressive form with generally poorer outcomes.
Women with the highest blood levels of PFOS had a 93% higher rate of ER-negative breast cancer than women with the lowest levels, nearly double. For PFOA, the rate was 67% higher.
These are relative differences between groups, not a woman’s personal risk, and the study shows a link, not proof that the chemicals cause cancer.
PFAS, or per- and polyfluoroalkyl substances, have been used since the mid-20th century in products such as nonstick pans, water-repellent fabrics, food packaging and firefighting foam. They barely break down, which earned them their nickname, and they build up in the body, where they can stay for years.
PFOA and PFOS are the two “legacy” PFAS, the ones most studied and most heavily restricted. Even so, measurable amounts remain in most people’s bodies.
The data came from the Sister Study, run by the National Institute of Environmental Health Sciences. Between 2003 and 2009 it enrolled 50,884 women aged 35 to 74 across the United States and Puerto Rico. None had cancer at the start, but every one had a sister or half-sister who had been diagnosed with breast cancer.
That design matters. Because the blood was drawn long before any diagnosis, the chemical levels could not have been changed by the cancer or its treatment. The team also checked its results against a meta-analysis of earlier studies, and the pattern held.
Lead investigator Alexandra White, an NIH Stadtman Investigator, said the findings indicate that certain legacy PFAS are associated with a higher risk of ER-negative breast cancer.
ER-negative tumors lack receptors for estrogen, so the hormone does not fuel their growth. They tend to be harder to treat, and much less is known about what raises the risk of developing them. That the link showed up only in these tumors suggests the chemicals may act through a route unrelated to hormones, possibly changes in gene activity or the immune system. The study did not test those mechanisms.
First author Che-Jung Chang, a former NIH research fellow, pointed out that PFAS exposure is “potentially modifiable,” meaning people can take steps to reduce it. Drinking water is one of the main routes, and a filter certified to reduce PFAS is one practical option where local water is known to be contaminated.
Questions about long-term risk keep coming up in women’s health. We recently covered new guidance on periods as a vital sign for heart health, and how the first mutation behind one leukemia can appear before age 20.
“More research is needed, particularly evaluating the risk of breast cancer,” White said, noting that the risks of the newer chemicals that replaced PFOA and PFOS are still unknown.
There are limits. All the women had a sister with breast cancer, so they are not a typical group, and the results may differ in women without that family history. Blood levels were measured once. The researchers say future work should look at communities with higher PFAS exposure and at groups with higher rates of ER-negative breast cancer.
The study was funded by the National Institute of Environmental Health Sciences.
Source
Chang CJ, Pullella K, Keil AP, et al. “Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study.” Journal of Clinical Oncology, 2026.
DOI: 10.1200/JCO-26-00318